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INTRODUCTION
Human tumors often display changes in DNA methylation, 
which include both genome-wide hypomethylation and 
site-specific hypermethylation. Global hypomethylation 
and CpG island hypermethylation have been recognized 
as important contributors to the development of  
carcinogenesis in humans. Hypermethylation of  promoter 
CpG islands is the signature of  transcriptional silencing 
of  their downstream genes, including RB, p16, VHL, 
BRCA1, E-cadherin, APC, hMLH1, FHIT, COX2, and 
CDX1 in various human cancers; and is as effective as 
inactivation by gene mutation or deletion[1-6]. Global DNA 
hypomethylation has been implicated in the activation of  
oncogenes such as c-myc, k-ras, and it may also contribute 
to tumor progression by the induction of  genome 
instability[7,8].
The MAGE family of  genes belongs to a group of  
germ line-specifi c genes that are activated in different types 
of  tumors. This family of  genes was reported to direct the 
expression of  a tumor-specifi c antigen that was recognized 
in a melanoma cell by cytolytic T lymphocytes[9]. The 
MAGE-A1 gene has a CpG-rich promoter, which, 
unlike classical CpG-rich promoters, is methylated in 
all normal somatic tissues, except for the placenta and 
testis. In contrast, the promoter region of  MAGE-A1 is 
completely unmethylated in testicular germ cells and in 
tumor cells that express the gene[10]. Demethylation, and 
therefore, activation of  MAGE-A1 in tumors appears 
to be a consequence of  the genome-wide demethylation 
process, since the expression of  this gene in tumor 
cells correlates with a decreased level of  overall DNA 
methylation[11]. A correlation between MAGE-A1 and 
MAGE-A3 expression and genome-wide hypomethylation 
has been observed in some types of  carcinomas[12,13]. 
The human MAGE-A1 and MAGE-A3 genes, which 
are located on chromosome X, are expressed in 29% and 
66%, respectively, of  human gastric cancer cells due to 
the hypomethylation of  the promoter region[12]. However, 
it is unknown if  this relationship is present in colorectal 
carcinomas.
In this study, we investigated the promoter methylation 
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Abstract
AIM: To verify the expression and methylation status of 
the MAGE-A1  and MAGE-A3  genes in colorectal cancer 
tissues and cancer cell lines.
METHODS: We evaluated promoter demethylation 
status of the MAGE-A1  and MAGE-A3  genes by RT-PCR 
analysis and methylation-specifi c PCR (MS-PCR), as well 
as sequencing analysis, after sodium bisulfi te modifi ca-
tion in 32 colorectal cancer cell lines and 87 cancer tis-
sues. 
RESULTS: Of the 32 cell lines, MAGE-A1  and MAGE-A3  
expressions were observed in 59% and 66%, respective-
ly. Subsequent to sodium bisulfi te modifi cation and MS-
PCR analysis, the promoter hypomethylation of MAGE-A1  
and MAGE-A3  was confirmed in both at 81% each. 
Promoter hypomethylation of MAGE-A1  and MAGE-A3  in 
colorectal cancer tissues was observed in 43% and 77%, 
respectively. Hypomethylation of MAGE-A1  and MAGE-A3  
genes in corresponding normal tissues were observed in 
2% and 6%, respectively. 
CONCLUSION: The promoter hypomethylation of MAGE 
genes up-regulates its expression in colorectal carcino-
mas as well as in gastric cancers and might play a signif-
icant role in the development and progression of human 
colorectal carcinomas.
© 2006 The WJG Press. All rights reserved.
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status of  MAGE-A1 and MAGE-A3 genes. A total of  32 
colorectal cancer cell lines were tested for hypomethylation 
of  the MAGE-A1 and MAGE-A3 genes promoter. 
In addition, we screened the methylation status of  the 
MAGE-A1 and MAGE-A3 genes promoter in 87 paired 
colorectal cancers and normal mucosal tissue samples.
MATERIALS AND METHODS
Cell cultures
A total of  32 colorectal cancer cell lines (Table 1) and 2 
gastric cancer cell lines (SNU-1 and SNU-5) were obtained 
from either the Korean Cell Line Bank (KCLB; Seoul, 
Korea) or the American Type Culture Collection (ATCC; 
Manassas, VA, USA). Sixteen SNU-colorectal cancer cell 
lines were established and were reported upon previously 
by this laboratory [14,15]. SNU-1 and SNU-5 gastric 
carcinoma cell lines were used as methylation positive 
(SNU-1) and negative (SNU-5) controls for MAGE 
gene expression[12]. All the cell lines were maintained in 
RPMI1640, which was supplemented with 10% FBS, 100 
kU/L penicillin, and 0.1 g/L streptomycin. The cultures 
were maintained in humidifi ed incubators at 37℃ in a 5% 
CO2 and 95% ambient air atmosphere. 
Nucleic acid isolation and cDNA synthesis from the cell 
lines
Genomic DNA and total RNA were isolated from 
washed-cell pellets. Total genomic DNA was extracted 
in accordance with the standard SDS-proteinase K 
procedure; and total cellular RNA was extracted based on 
the manufacturer’s instructions (Intron Biotechnology; 
Seoul, Korea). For cDNA synthesis, 2 μg of  total RNA 
was reverse transcribed with a random hexamer, dNTPs, 
and 1 μL (200 U) of  SuperscriptTM II reverse transcriptase 
(Life Technologies; Gaithersburg, MD, USA) in a final 
volume of  20 μL for 1 h and 15 min at 42℃ after a 
10-min denaturation at 70℃. Eighty microliters of  distilled 
water were added subsequent to the reverse-transcription 
reaction. 
Expression of MAGE-A1 and MAGE-A3 genes
For mRNA expression analysis, the cDNA was amplifi ed 
in 25 μL of  a PCR reaction mix with 1 μL of  the reverse-
transcription reaction, the primers and 0.5 U of  Taq DNA 
polymerase. The PCR conditions consisted of  10 min at 
94℃ for the initial denaturation, followed by 35 cycles 
of  94℃ for 30 s, 54℃ for 60 s, and 72℃ for 60 s, and a 
fi nal elongation of  7 min at 72℃. The primer sequences 
are as follows. MAGE-A1 cDNA was amplifi ed by PCR 
with MG1 RT primers; MG1 RT sense, 5’-TGTGG
GCAGGAGCTGGGCAA-3’, MG1 RT antisense, 5’- 
GCCGAAGGAACCTGACCCAG -3’. For the MAGE-A3 
cDNA, the MG3 RT primers were used; MG3 RT 
sense, 5’-AAGCCGGCCCAGGCTCGGT-3’, MG3 RT 
antisense, 5’-GCTGGGCAATGGAGACCCAC-3’. PCR 
amplifi cation was performed in a programmable thermal 
cycler (PCR System 9700, Applied Biosystems; Foster City, 
CA, USA). Primers for β -actin were used to confi rm RNA 
integrity. Both MAGE-A1 and MAGE-A3 and β -actin 
RT-PCR reactions used the same cDNA synthesis. The 
amplifi ed DNA fragments were fractionated in 2% agarose 
gel and stained with ethidium bromide.
Tissue sample collection and DNA extraction
A total of  87 paired tumor and normal mucosal tissue 
samples were obtained from 87 patients, who had primary 
colorectal adenocarcinoma. The normal mucosal tissue 
specimens were collected from each patient 10 cm or more 
away from the tumor areas. Approximately 2 g of  the 
surgically removed tissues were frozen immediately and 
then stored in liquid nitrogen. The remaining sections of  
the samples were fi xed with formalin and used for further 
histological examination in order to confi rm the diagnosis 
postoperatively. Genomic DNA was isolated from the 
frozen-tissue biopsies with the standard SDS-proteinase K 
procedure. 
Methylation specifi c PCR 
With respect to the MS-PCR, the sodium bisulfite 
modification of  genomic DNA was performed as 
reported previously[16]. A total of  2 μg of  genomic DNA 
obtained from colorectal cancer cell lines, was denatured 
with NaOH and hydroquinone. Then, 3 mmol/L sodium 
bisulfi te was added and the mixture was incubated at 55℃ 
for 16 h. Following the bisulfi te modifi cation, the DNA 
was purified with a Wizard DNA purification system 
(Promega; Madison, WI, USA), ethanol precipitated, 
dried, and resuspended in 100 μL distilled water. The 
PCR was performed using the PCR primers that were 
described previously[12]. The amplified DNA fragments 
were fractionated in 2% agarose gel that was stained with 
ethidium bromide and visualized under UV light. 
5-aza-2’-deoxycytidine treatment and RT-PCR
For 5-aza-2’-deoxycytidine treatment, the cells were seeded 
in two 2 × 105 cells/75 cm2 culture fl asks on d 0. The cells 
were treated with and without 1-5 μmol/L of  5-aza-2’
-deoxycytidine (Sigma Chemical Co.) for 24 h on d 2 and 
5, and the medium was changed 24 h after addition of  
5-aza-2’-deoxycytidine. The cells were harvested on d 8 
for the analysis of  the MAGEs expression. Subsequently, 
the RNA was prepared, and RT-PCR was performed to 
detect MAGE-A1 and MAGE-A3 expression with the 
MAGE-A1 and MAGE-A3 RT-PCR primers as described 
above.
RESULTS
Expression of MAGE-A1 and MAGE–A3 in colorectal 
cancer cell lines
Expression of  MAGE-A1 and MAGE-A3 mRNA in 32 
colorectal cancer cell lines was analyzed by RT-PCR, and 
MAGE-A1 and MAGE-A3 expressions were observed 
in 19 (59%) and 21 (66%) of  the cell lines, respectively 
(Figure 1 and Table 1). PCR for β -actin confirmed the 
integrity of  the RNA.
Clinico-pathological features
Of  the 87 colorectal carcinomas, 57 (66%) were obtained 
from the proximal colon (cecum to splenic fl exure), and 
30 (34%) from the distal colorectum (splenic flexure to 
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rectum). Randomly selected patients aged 16-81 years, 
including 55 males and 32 females. Of  the 32 colorectal 
cancer cell lines, 7 originated from the proximal colon and 
8 from the distal colorectum. The origin of  the remaining 
17 colorectal cancer cell lines was unknown. 
Analysis of MAGE-A1 and MAGE-A3 methylation by MS-
PCR
By using primers for unmethylated MAGE-A1 DNA 
amplification on bisulfite modified DNA, amplified 
DNA fragments were observed in 26 (81%) cell lines 
(SNU-61, SNU-175, SNU-283, SNU-503, SNU-769A, 
SNU-769B, SNU-1033, SNU-1197A, SNU-C1, SNU-
C2A, SNU-C5, Caco2, COLO201, COLO205, COLO320, 
DLD-1, HCT-15, HCT-116, HT-29, Lovo, LS174T, 
NCI-H716, SW403, SW480, SW1116, and WiDR) (Figure 
2 and Table  1). And by using primers for unmethylated 
MAGE-A3 DNA amplification on bisulfite modified 
DNA, amplified DNA fragments were found also in 26 
(81%) cell lines (SNU-61, SNU-175, SNU-407, SNU-503, 
SNU-769A, SNU-769B, SNU-1033, SNU-1047, SNU-
1197A, SNU-C1, SNU-C2A, SNU-C4, Caco2, COLO201, 
COLO205, COLO320, DLD-1, HCT-15, HCT-116, 
HT-29, Lovo, LS174T, NCI-H716, SW403, SW1116, 
and WiDR) (Figure 2 and Table  1). By using primers 
for amplification of  unmethylated or methylated DNA, 
amplifi ed DNA fragments were found in all 32 cell lines. 
MAGE-A1 unmethylated DNA products were observed 
in 37 out of  87 tumor tissue samples (43%; Figure 3). 
In the normal tissue samples, the methylated DNA was 
amplified in all 87 samples. However, the unmethylated 
DNA was amplifi ed in 2 normal tissues (2%). MAGE-A3 
unmethylated DNA products were observed in 67 out of  
87 tumor tissue samples (77%; Figure 3). In the normal 
tissue samples, the methylated DNA was amplifi ed in all 87 
samples. However, the unmethylated DNA was amplifi ed 
in 5 normal tissues (6%). 
Reexpression of MAGE-A1 and MAGE-A3 after treatment 
with 5-aza-2’-deoxycytidine 
We investigated whether MAGE-A1 mRNA was re-
expressed after 5-aza-2’-deoxycytidine treatment in 22 cell 
Table 1  Methylation status of the promoter region of MAGE-A1 and MAGE-A3 genes in 32 colorectal cancer cell lines
　
Cell line
MAGEs expression 　 MS-PCR 　
MAGE-A1 MAGE-A3 MAGE-A1 MAGE-A3
　 -5-aza/+5-aza 　 - 5-aza/+5-aza 　 M/U 　 M/U 　
  1 SNU-61 - ++ ± ++ + + - +
  2 SNU-81 - ++ - +++ + - + -
  3 SNU-175 ++ ++ +++ +++ + + + +
  4 SNU-283 +++ NT +++ NT + + + -
  5 SNU-407 +++ + +++ ++ + - + +
  6 SNU-503 ++ NT - NT + + + +
  7 SNU-769A +++ ++ +++ +++ - + - +
  8 SNU-769B +++ +++ +++ +++ - + - +
  9 SNU-1033 ++ + ++ +++ + + + +
10 SNU-1040 - - ± ++ + - + -
11 SNU-1047 +++ ++ ++ ++ + - - +
12 SNU-1197 ++ +++ ++ +++ + + + +
13 SNU-C1 ± NT ++ NT + + - +
14 SNU-C2A ++ NT +++ NT + + + +
15 SNU-C4 - NT - NT + - + +
16 SNU-C5 ± ++ - +++ + + + -
17 Caco-2 - ++ ++ +++ + + + +
18 COLO201 - ++ - +++ - + - +
19 COLO205 - - - ++ + + + +
20 COLO320 +++ NT +++ NT + + - +
21 DLD-1 - +++ - +++ + + + +
22 HCT-8 - ++ - +++ + - + -
23 HCT-15 - ++ - +++ + + + +
24 HCT-116 +++ NT +++ NT + + + +
25 HT-29 +++ ++ +++ +++ + + + +
26 Lovo +++ +++ +++ +++ + + + +
27 LS174T +++ NT +++ NT + + - +
28 NCI-H716 +++ +++ +++ +++ + + - +
29 SW403 +++ ++ +++ +++ + + + +
30 SW480 +++ NT +++ NT + + + -
31 SW1116 - NT ++ NT + + - +
32 WiDR ++ +++ 　 +++ +++ 　 + + 　 - + 　
5-aza: 5-aza-2’-deoxycytidine; NT: Not tested; M: The amplifi ed product with primers recognizing methylated sequence; U: The amplifi ed product with 
primers recognizing unmethylated sequence; +: Amplifi ed product; -: Not amplifi ed product.
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lines, including 10 cell lines (SNU-61, SNU-81, SNU-1040, 
SNU-C5, Caco-2, COLO201, COLO205, DLD1, 
HCT-8, and HCT-15) that did not express MAGE-A1 
mRNA. After an RT-PCR analysis, we observed that all 
of  the MAGE-A1 mRNAs were re-expressed, except 
for the SNU-1040 and COLO205 cell lines (Table 1). 
This suggested that the inactivation of  MAGE-A1 
expression was caused by another mechanism. Further, 
we investigated whether MAGE-A3 mRNA was re-
expressed after 5-aza-2’-deoxycytidine treatment in 22 cell 
lines, including 9 cell lines (SNU-61, SNU-81, SNU-1040, 
SNU-C5, COLO201, COLO205, DLD1, HCT-8, and 
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Figure 1  RT-PCR analysis of the MAGE-A1 and MAGE-A3 genes in 32 colorectal cancer cell lines. β-actin was amplifi ed as an internal control. The MAGE-A1 gene was 
signifi cantly expressed in 19 colorectal cancer cell lines (Lanes, 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 20, 24, 25, 26, 27, 28, 29, 30 and 32). The MAGE-A3 gene was expressed 
in 21 colorectal cancer cell lines (Lanes, 3, 4, 5, 7, 8, 9, 11, 12, 13, 14, 17, 20, 24, 25, 26, 27, 28, 29, 30, 31 and 32). Lane numbers 1 to 34 show cell lines SNU-61, 
SNU-81, SNU-175, SNU-283, SNU-407, SNU-503, SNU-769A, SNU-769B, SNU-1033, SNU-1040, SNU-1047, SNU-1197, SNU-C1, SNU-C2A, SNU-C4, SNU-C5, Caco-2, 
COLO201, COLO205, COLO320, DLD1, HCT-8, HCT-15, HCT-116, HT-29, LOVO, LS174T, NCI-H716, SW403, SW480, SW1116, WiDr, SNU-1, and SNU-5 respectively.
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Figure 2  Methylation analysis of the MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines. The promoter region of the MAGE-A1 gene was unmethylated in 26 cell 
lines (SNU-61, SNU-175, SNU-283, SNU-503, SNU-769A, SNU-769B, SNU-1033, SNU-1197A, SNU-C1, SNU-C2A, SNU-C5, Caco2, COLO201, COLO205, COLO320, 
DLD-1, HCT-15, HCT-116, HT-29, Lovo, LS174T, NCI-H716, SW403, SW1116, and WiDR cell lines). Unmethylated MAGE-A3 DNA amplifi cations were found in 26 cell 
lines (SNU-61, SNU-175, SNU-407, SNU-503, SNU-769A, SNU-769B, SNU-1033, SNU-1047, SNU-1197A, SNU-C1, SNU-C2A, SNU-C4, Caco2, COLO201, COLO205, 
COLO320, DLD-1, HCT-15, HCT-116, HT-29, Lovo, LS174T, NCI-H716, SW403, SW1116, and WiDR cell lines). Lane M denotes product amplifi ed by primers recognizing a 
methylated sequence and Lane U denotes the product amplifi ed by primers recognizing an unmethylated sequence, respectively.
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HCT-15) that did not express MAGE-A3 mRNA. After an 
RT-PCR analysis, we observed that all of  the MAGE-A3 
mRNAs were re-expressed (Table 1 and Figure 4). 
DISCUSSION
Genome-wide hypomethylat ion and s i te-specif ic 
hypermethylation are common features of  cancer cells. 
DNA hypomethylation in cancer cells is accompanied 
by the activation of  germ line-specifi c genes, such as the 
MAGE-A1 gene, the repression of  which, in normal 
somatic tissues, is dependent upon DNA methylation[17]. 
Recent studies have reported the presence of  very high 
MAGE-A1 and MAGE-A3 expressions in colorectal 
carcinomas[18,19]. Although previous reports have shown 
the expression of  MAGE genes, the mechanism of  
MAGE genes expression in colorectal carcinomas was 
unclear. This led us to question whether it could be 
associated with decreased genomic methylation. It has 
been reported that MAGE-A1 and MAGE-A3 expression 
was related to gene hypomethylation in gastric carcinoma, 
hepatocarcinoma, and melanoma[12,20,21]. However, such 
a relationship has still not been confirmed in colorectal 
carcinoma. Accordingly, we analyzed the methylation 
status of  the promoter region on the MAGE-A1 and 
MAGE-A3 genes in 32 colorectal cancer cell lines and 
estimated its association with MAGE-A1 and MAGE-A3 
mRNA expression. We first examined the expression 
pattern of  the MAGE-A1 and MAGE-A3 genes in these 
cell lines by an RT-PCR and observed that MAGE-A1 and 
MAGE-A3 were over-expressed signifi cantly in 19 (59%) 
and 21 (66%) cell lines, respectively. This expression ratio 
of  MAGE-A1 and MAGE-A3, obtained by an RT-PCR 
in colorectal cancer cell lines, is similar to that observed 
in gastric cancer cell lines[12]. On the other hand, previous 
reports have revealed a much lower expression of  MAGE 
in colorectal carcinomas ranging between 5%-39%[18,19,22]. 
In the literature, the expression of  the MAGE genes 
was studied in colorectal carcinoma tissues; however, we 
have tested that in cancer cell lines. We assume that the 
major discrepancy of  expression rates of  MAGE genes 
between other reports and our fi ndings might result from 
this. Since RNA or DNA was extracted from surgically 
removed frozen tissue biopsies, the tumor tissues may have 
been contaminated with normal stromal cells, therefore, 
masking the true levels of  hypomethylation or expression 
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Figure 3  Methylation analysis of the MAGE-A1 and MAGE-A3 genes in colorectal cancer tissues and corresponding normal tissues. Methylation-specifi c PCR product 
amplifi ed by primers recognizing methylated and unmethylated sequence. The promoter region of the MAGE-A1 and MAGE-A3 genes was unmethylated in colorectal 
cancer tissues, not normal tissues. Numbers represent each colorectal tissue and T denotes colorectal tumor tissues and N denotes corresponding normal tissues.
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Figure 4  RT-PCR analysis after treatment 
with 5-aza-2’-deoxycytidine. The MAGE-A1 
and MAGE-A3 genes were reactivated.
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of  the MAGE genes in cancer tissues[23]. For further 
analysis of  the methylation status of  the MAGE genes 
in colorectal cancer tissues, laser capture microdissection 
techniques would allow more precise isolation of  cancer 
cells and normal cells. It has already been reported that 
cancer cell lines have much higher levels of  CpG island 
hypermethylation than corresponding malignant tissues, 
which may explain our lower incidence of  hypomethylation 
in tissues versus cell lines. Moreover, cancer cells might 
be clonally selected with growth advantages over cancer 
cell lines. However, cancer cell lines often preserve 
hypermethylation or hypomethylation from the tumors 
they originate, thus they are indeed useful tools to study 
methylation status.
We ana lyzed promoter unmethy la t ion of  the 
MAGE-A1 and MAGE-A3 genes with a methylation-
specific PCR after sodium-bisulfite modification and by 
direct sequencing analysis. Of  the 32 cell lines analyzed, 
the promoter hypomethylation of  MAGE-A1 and 
MAGE-A3 was observed in both at 26 cell lines each. 
Further, 23 cell lines (SNU-61, SNU-175, SNU-503, 
SNU-769A, SNU-769B, SNU-1033, SNU-1197A, 
SNU-C1, SNU-C2A, Caco2, COLO201, COLO205, 
COLO320, DLD-1, HCT-15, HCT-116, HT-29, Lovo, 
LS174T, NCI-H716, SW403, SW1116, and WiDR) were 
simultaneously unmethylated in both the MAGE-A1 and 
MAGE-A3 genes. With exception, there were two cell 
lines (SNU-61, COLO201) with negative gene expression 
for either MAGE-A1 or MAGE-A3, but unmethylated 
MAGE-A1 or MAGE-A3 promoter was detected. On the 
contrary, there were four cell lines (SNU-283, SNU-407, 
SNU-1047 and SW480) in which MAGE genes were 
strongly expressed, although no unmethylated MAGE 
promoter could be detected, suggesting the activation or 
inactivation of  MAGE expression by another mechanism.
In our study, the rates of  hypomethylation of  the 
MAGE-A1 and MAGE-A3 genes in colorectal cancer 
cell lines were 81% in both and those in colorectal cancer 
tissues were 43% and 77%, respectively. The DNA was 
extracted from the surgically removed frozen-tissues; 
however, the tumor tissues might have been contaminated 
with some normal stromal cells. Therefore, the levels of  
hypomethylation of  MAGE-A1 and MAGE- A3 genes in 
cancer tissues might be affected by the DNA from normal 
cells. To obtain a better understanding of  the promoter 
hypomethylation status of  the MAGE-A1 and MAGE-A3 
genes in colorectal cancer tissues, expression analysis of  
MAGE-A1 and MAGE-A3 (such as, in situ hybridization 
or immunostaining) and the more precise methylation 
analysis method (such as, laser capture microdissection 
techniques) to isolate cancer cells from normal cells need 
to be performed. The hypomethylation of  the MAGE-A1 
and MAGE-A3 genes in corresponding normal tissues was 
detected in only 2 and 5 samples (2% and 6%), respectively 
(Table 2). 
To evaluate the association between the clinical 
parameters and MAGE expression, the Pearson χ2 test 
was used to evaluate differences in tumor location (proximal 
or distal) or gender, and signifi cance was determined using 
95% confidence intervals. In our study, unmethylated 
MAGE-A1 DNA expression was significantly different 
in respect of  tumor location and gender. Unmethylated 
MAGE-A1 DNA expression was significantly higher in 
distal location (P = 0.028) and in females (P = 0.004). 
However, unmethylated MAGE-A3 DNA expression was 
not signifi cantly associated with tumor location (P = 0.239), 
while it was only related to female gender (P = 0.021).
Our results supported the role of  the promoter 
methylation in maintaining a silent phenotype of  the 
MAGE-A1 and MAGE-A3 genes, as the MAGE 
gene was re-expressed after treatment with 5-aza-2'-
deoxycytidine. This agent reactivates gene expression 
when methylation of  CpG islands is the cause of  reduced 
gene expression. We demonstrated that the MAGE-A1 
and MAGE-A3 mRNAs were re-expressed after 5-aza-2'-
deoxycytidine treatment in all 8 and 9 cell lines that did not 
express MAGE-A1 and MAGE-A3 mRNAs, respectively. 
However, the SNU-1040 and COLO 205 cell lines did 
not show re-expression, suggesting the inactivation of  
MAGE-A1 expression by another mechanism.
In conclusion, we observed hypomethylation in 
the promoter region of  both the MAGE-A1 and 
MAGE-A3 genes in 23 of  32 colorectal cancer cell 
lines. This methylation was confirmed by MS-PCR, 
treatment with 5-aza-2’-deoxycytidine, and bisulfi te direct 
sequencing analysis. Hypomethylation of  the promoter 
region appears to be a frequent phenomenon in human 
colorectal cancers and upregulates transcription of  the 
MAGE-A1 and MAGE-A3 genes in colorectal cancer 
cells. In addition, out of  87 colorectal cancer tissues, we 
observed hypomethylation in the promoter regions of  
the MAGE-A1 and MAGE-A3 genes in 37 (43%) and 67 
(77%) tissues, respectively. This suggests that promoter 
hypomethylation of  MAGE-A1 and MAGE-A3 genes up-
regulates its expression in colorectal carcinomas as well 
as in gastric cancers, and might play a signifi cant role in 
the development and progression of  human colorectal 
carcinomas.
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